Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time‐limited venetoclax/obinutuzumab treatment
Abstract The novel time‐limited combinations with the bcl‐2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient.
Main Authors: | Maria Dimou, Theodoros Iliakis, Vasileios Paradalis, Aikaterini Bitsani, Marie‐Christine Kyrtsonis, Panayiotis Panayiotidis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4514 |
Similar Items
-
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01) -
An unusual presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma on mammography: Case report
by: Anas Mohamed, et al.
Published: (2021-07-01) -
Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01) -
Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
by: Lili Kotmayer, et al.
Published: (2023-03-01) -
Deep Learning for the Classification of Non-Hodgkin Lymphoma on Histopathological Images
by: Georg Steinbuss, et al.
Published: (2021-05-01)